Covaxin cleared for emergency use in 2-18 age group
Part of: Prelims and GS II – Health
Context Bharat Biotech’s COVID-19 vaccine Covaxin (BBV152) has been recommended for emergency use authorisation (EUA) for 2-18-year-olds by the Subject Expert Committee (SEC) of the Central Drugs Standards Control Organisation (CDSCO).
Once approved, it will emerge as the first COVID-19 vaccine globally to be used for vaccinating children as young as 2 years.
What is the Central Drugs Standards Control Organisation (CDSCO)?
The Central Drugs Standard Control Organisation (CDSCO)under the Directorate General of Health Services, Ministry of Health & Family Welfare, is the National Regulatory Authority (NRA) of India.
Under the Drugs and Cosmetics Act, CDSCO is responsible for approval of Drugs, Conduct of Clinical Trials, laying down the standards for Drugs,
Headquarters: New Delhi
About Covaxin
Covaxin is India’s first indigenous, whole-virion, inactivated vaccine developed by Bharat Biotech in collaboration with the Indian Medical Research Council (ICMR) and the National Institute of Virology (NIV).
It has been formulated with ‘Algel-IMDG’, which contains chemically absorbed TLR7/8 as an adjuvant onto aluminium hydroxide gel to generate the requisite type of immune responses without damaging the body.
